Drug Delivery Technologies

Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, to the FDA.  The company expects the agency will perform an expedited review of its ANDA, and ...

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) shared results from majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of its proprietary R-ketamine compound PCN-101. See Also: Breaking Ground In Prevention &...

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug SPC-15.  The company aims to combine the liquid nasal formulation and SPC-15’s novel...

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech...

Drug delivery company IntelGenx Technologies Corp. (OTCQB: IGXT)’s financial results for the three and twelve months ended December 31, 2022 show:  Total cash and short-term investments of $2.5 million by Dec. 31, 2022, not including the $3.0 million loan by atai Life Sciences (NASDAQ...

Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through PharmaTher's microneedle patch technology. PharmaDrug has said that the DMT...

Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies. The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd.  The exclusive agreement is set to design and conduct two Phase...

Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral, fast-dissolving tablet Zydis technology. The new drug delivery platform is a freeze-dried, oral solid dosage form that rapidly...

Specialty ketamine company PharmaTher Holdings Ltd. (OTCQB: PHRRF) submitted its Type B meeting package to the FDA to discuss the remaining requirements for the KETARX on-body pump system and submit the corresponding New Drug Application (NDA) under the 505(b)(2) pathway by the end of 2023. See...

Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) has begun an investigative study on the dissociative effect of a proprietary and patent-pending formulation of (S)-ketamine, as well as an optimized...

Psychedelics R&D biotech Biomind Labs Inc. (OTC: BMNDF) has completed the development of a novel sublingual formulation and the first production batch for testing in its Phase 2 trial on proprietary 5-MeO-DMT-based drug candidate, BMND08, for the treatment of depression and anxiety states in...

Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD). Through its R&D acceleration platform,...

Drug delivery company IntelGenx Corp. (OTCQB: IGXT)’s development candidate buprenorphine buccal film, for which an Abbreviated New Drug Application (ANDA) has been filed by Chemo Research SL through its agent and affiliate generic pharma products company Xiromed LLC (the US division of Insud...

SEVALENT, Bexson Biomedical’s disrupting offer ready for the small molecule injectable market, received patent allowance by the USPTO for “Complexing Agent Salt Formulations of Pharmaceutical Compounds.”  The company’s formulation technology enables wearable, home...

As competence grows, biopharmaceuticals are searching for ways to present their specific psychedelic substance-assisted therapies in a way that might differentiate them from their competitors while maintaining safety and efficiency standards. In this sense, Awakn Life Sciences Corp. (OTCQB: AWKNF...